F2R and breast carcinoma: To apply IHC with anti-PAR1-QDs in a clinical setting, we selected four normal breast tissue samples from breast cancer patients, five HER2-negative breast cancer cases that remained non-metastatic for more than 5 years after surgery, and eleven HER2-negative cases with metastasis within 3 years after surgery, including seven triple-negative cases.